This study deal with introducing a novel biocompatible porous nanomaterial for anticancer drug delivery. For this purpose, a porous covalent triazine framework (CTF) was prepared by a solvothermal reaction. The structure and morphology characterization of the synthesized CTF was done through different techniques. Imatinib (IMA) were loaded thoroughly into the CTF to form IMA-loaded CTF (IMA@CTF) in which drug loading and encapsulation efficiency was calculated to be 82% and 96%, respectively. The releases of 73% and 48%% after 72 h for the IMA@CTF were obtained in pH = 5.3 and pH = 7.4, respectively, which reflected pH-dependent behavior as well as sustained imatinib release. Biocompatibility and cytotoxicity effect of CTF and IMA@CTF assessed after 48 h incubation with normal cell line L929 as well as K562 cells. The biocompatibility study indicated reasonable biosafety of the synthesized CTF and MTT assay on chronic myeloma cancer cells showed no reduction effect in the anticancer activity of IMA after incorporating into CTF. The results demonstrated the synthesized CTF could be as a promise anti-cancer drug carrier.

中文翻译：

---

新型纳米级香草醛基共价三嗪框架作为伊马替尼缓释的新型载体

本研究涉及引入一种用于抗癌药物输送的新型生物相容性多孔纳米材料。为此，通过溶剂热反应制备了多孔共价三嗪骨架 (CTF)。合成的 CTF 的结构和形态表征是通过不同的技术完成的。伊马替尼 (IMA) 被彻底加载到 CTF 中，形成加载 IMA 的 CTF (IMA@CTF)，其中载药率和包封率分别为 82% 和 96%。IMA@CTF 在 pH = 5.3 和 pH = 7.4 下分别在 72 小时后释放 73% 和 48%，这反映了 pH 依赖性行为以及持续的伊马替尼释放。CTF 和 IMA@CTF 在与正常细胞系 L929 和 K562 细胞孵育 48 小时后评估的生物相容性和细胞毒性作用。生物相容性研究表明合成的 CTF 具有合理的生物安全性，MTT 法对慢性骨髓瘤癌细胞的检测表明，IMA 掺入 CTF 后的抗癌活性没有降低。结果表明合成的CTF可以作为一种有前途的抗癌药物载体。